Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
T2 Biosystems, Inc. (TTOO)
|
Add to portfolio |
|
|
|
| Price: |
$1.38
| | Metrics |
| OS: |
333.6
|
M
| |
|
|
| Market cap: |
$460
|
M
| |
|
|
|
Net debt:
|
$34.5
|
M
| |
|
|
|
EV:
|
$495
|
M
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
($52.1)
|
M
| |
|
|
| EPS |
($4.94)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 22.3 | 28.1 | 18.1 | 8.3 | 10.5 | 4.7 | 4.1 | 2.8 |
| Revenue growth | -20.5% | 54.8% | 117.5% | -20.6% | 125.0% | 14.4% | 45.0% | 2263.9% |
| Cost of goods sold | 77.5 | 71.0 | 21.3 | 16.8 | 15.4 | 12.0 | 6.9 | 1.7 |
| Gross profit | -55.2 | -43.0 | -3.2 | -8.4 | -4.9 | -7.4 | -2.8 | 1.1 |
| Gross margin | -247.4% | -153.2% | -17.4% | -101.1% | -46.7% | -157.8% | -68.4% | 38.1% |
| Selling, general and administrative | 0.0 | 0.0 | 22.1 | 27.3 | 25.7 | 22.8 | 24.1 | 19.1 |
| Research and development | | | 16.1 | 16.3 | 14.5 | 23.7 | 24.0 | 25.4 |
| EBIT | -61.9 | -49.2 | -41.4 | -52.1 | -45.1 | -53.9 | -50.9 | -43.4 |
| EBIT margin | -277.6% | -175.5% | -228.1% | -624.6% | -429.4% | -1154.1% | -1247.0% | -1542.2% |
| Pre-tax income | -62.0 | -49.2 | -46.8 | -59.0 | -51.2 | -62.4 | -54.8 | -45.3 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -62.0 | -49.2 | -46.8 | -59.0 | -51.2 | -62.4 | -54.8 | -45.3 |
| Net margin | -278.0% | -175.5% | -258.1% | -707.9% | -487.2% | -1337.9% | -1343.2% | -1610.0% |
| |
| Diluted EPS | ($12.16) | ($15.50) | ($0.39) | ($1.30) | ($1.26) | ($1.94) | ($2.11) | ($2.21) |
| Shares outstanding (diluted) | 5.1 | 3.2 | 121.3 | 45.5 | 40.6 | 32.1 | 26.0 | 20.5 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|